[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beta Bionics Inc (BBNX)

Beta Bionics Inc (BBNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 746,859
  • Shares Outstanding, K 44,562
  • Annual Sales, $ 100,250 K
  • Annual Income, $ -73,200 K
  • EBIT $ -77 M
  • EBITDA $ -74 M
  • 60-Month Beta 3.04
  • Price/Sales 7.42
  • Price/Cash Flow N/A
  • Price/Book 2.74

Options Overview Details

View History
  • Implied Volatility 114.69% (-5.91%)
  • Historical Volatility 74.07%
  • IV Percentile 23%
  • IV Rank 13.43%
  • IV High 434.18% on 03/12/26
  • IV Low 65.12% on 12/26/25
  • Expected Move (DTE 13) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 3,174
  • Open Int (30-Day) 3,053
  • Expected Range 16.76 to 16.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.62
  • Number of Estimates 4
  • High Estimate $-0.57
  • Low Estimate $-0.66
  • Prior Year $-0.39
  • Growth Rate Est. (year over year) -58.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.26 +36.70%
on 06/04/26
17.18 -2.44%
on 06/29/26
+3.97 (+31.04%)
since 06/02/26
3-Month
8.80 +90.45%
on 04/10/26
17.18 -2.44%
on 06/29/26
+6.83 (+68.78%)
since 04/02/26
52-Week
8.80 +90.45%
on 04/10/26
32.71 -48.76%
on 11/26/25
+2.62 (+18.53%)
since 07/02/25

Most Recent Stories

More News
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

SAN DIEGO , July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation...

BBNX : 16.76 (+0.36%)
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026

IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to...

BBNX : 16.76 (+0.36%)
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

SAN DIEGO , June 22, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation...

BBNX : 16.76 (+0.36%)
Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or...

BBNX : 16.76 (+0.36%)
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

SAN DIEGO , June 12, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation...

BBNX : 16.76 (+0.36%)
Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel

Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The investigation focuses on investors’ losses and...

BBNX : 16.76 (+0.36%)
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO , June 2, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP  is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors...

BBNX : 16.76 (+0.36%)
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website

IRVINE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-time...

BBNX : 16.76 (+0.36%)
Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Shareholder Rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and...

BBNX : 16.76 (+0.36%)
Beta Bionics Updates Commercialization Timeline Expectations for Mintâ„¢, its Patch Pump in Development

IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to...

BBNX : 16.76 (+0.36%)

Business Summary

Beta Bionics Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of solutions. Beta Bionics Inc. is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 18.04
2nd Resistance Point 17.55
1st Resistance Point 17.16
Last Price 16.76
1st Support Level 16.27
2nd Support Level 15.78
3rd Support Level 15.38

See More

52-Week High 32.71
Fibonacci 61.8% 23.58
Fibonacci 50% 20.75
Fibonacci 38.2% 17.93
Last Price 16.76
52-Week Low 8.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.